Trillium Therapeutics Inc (TRIL.TO) Buy, Sell…

Trillium Therapeutics Inc (TRIL.TO)

23.33

+0.11 (0.47%)

as of Nov 19, 2021, 9:00:00 pm Market Open.

8 watching

COMMENT

Pfizer bought it today, and TRIL shares tripled from $6 to $18 in the blink of an eye. That's why he always advises investing in small drug companies; sometimes they pan out.

HOLD

(Market Call Minute.) Volatile stock and you can hold it if it hangs in there but be careful.

WATCH

Fascinated by the technology, they’re taking 2 off patent drugs and combining them to use in therapy for stroke victims. Has a lot of potential. Still has some huge upside.

Showing 1 to 3 of 3 entries

Trillium Therapeutics Inc (TRIL.TO) Frequently Asked Questions

What is Trillium Therapeutics Inc stock symbol?

Trillium Therapeutics Inc is a Canadian stock, trading under the symbol TRIL.TO (previously TRIL-T on Stockchase) on the Toronto Stock Exchange (TRIL-CT). It is usually referred to as TSX:TRIL or TRIL.TO

Is Trillium Therapeutics Inc a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on TRIL.TO (previously TRIL-T on Stockchase) on Stockchase. Read the latest expert commentary for Trillium Therapeutics Inc.

Is Trillium Therapeutics Inc a good investment or a top pick?

Trillium Therapeutics Inc was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Trillium Therapeutics Inc.

Why is Trillium Therapeutics Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Trillium Therapeutics Inc.

Is Trillium Therapeutics Inc worth watching?

Trillium Therapeutics Inc is followed by 8 investors on Stockchase and is a trending stock that is worth watching.

What is Trillium Therapeutics Inc stock price?

On 2021-11-19, Trillium Therapeutics Inc (TRIL.TO) stock closed at a price of $23.33.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Trillium Therapeutics Inc (TRIL.TO)